Digital Health Global
JANUARY 24, 2024
Biotech Showcase is true to its name – great companies are highlighted.” Tina Elder, Global Managing Director, EBD Group US, said, “Biotech Showcase has once again shown itself to be the premiere destination for innovators and partners to access a powerful network of industry decision-makers, media and top investors.
Healthcare IT Today
FEBRUARY 22, 2024
Whether they are digital health, medical device, biotech, or pharma companies, healthtech has costly and inefficient sales processes that often stem from a lack of foundational data & insights to reach the right target markets efficiently and effectively. physicians, physician groups, hospitals, health systems, etc).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
MARCH 2, 2023
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. We look for similar customer-oriented ethos and patient-centric mindsets in our partnerships,” said Kim Kushner, Chief Business Officer, SSI Strategy. Learn more at koneksahealth.com.
Digital Health Global
APRIL 5, 2024
ADT Biotech 7.5 Mesa Biotech (Thermo Fisher) 7.42 Mesa Biotech (Thermo Fisher) 7.42 The research provides an in-depth look at the current and future market participants driving growth in this sector. Announces Two Acquisitions 6.36 Nigerian Govt Approves Alere HIV Self-Test Kit 6.37 Tasso scores $6.1M 1DropDiagnostics 7.2
Health Populi
APRIL 26, 2022
The press release lists the names of each of the 47 individual pharma companies assessed, such as Big Pharma leaders like AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, Novartis, and Pfizer, along with companies associated with biotech like Amgen, Biogen, Genentech, and Gilead. Generics such as Mylan and Teva, among others.
Lloyd Price
NOVEMBER 10, 2018
One of the biggest gambles in biotech history is about to be tested on Wall Street. In its prospectus, Moderna set an initial target of $500 million for the offering, which would make it the largest biotech IPO in history. This has all been part of a high-stakes strategy by Moderna and its backers. We believe we can.”
Digital Health Global
APRIL 25, 2024
About Koneksa Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enable efficient clinical trial designs to help innovative therapies reach patients faster.
Expert insights. Personalized for you.
88 
Let's personalize your content